2022 Fiscal Year Final Research Report
Development of novel anti-tumor agent to overcome multiple myeloma
| Project/Area Number |
20K06939
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 47010:Pharmaceutical chemistry and drug development sciences-related
|
|---|
| Research Institution | Osaka Metropolitan University (2022)
Osaka City University (2020-2021) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | マクロライド / 多発性骨髄腫 / 医薬化学 / 天然物合成 |
|---|
| Outline of Final Research Achievements |
Ynone-LLZ which was developed based on the natural 14-membered macrolide, LL-Z-1640-2, by the author displays the potent anti-tumor activity against multiple myeloma cells in vitro and in vivo. However, the biomolecular target of Ynone-LLZ and the mode of action are still unknown. In this research, the author tried to synthesize the chemical probe containing alkyne tag for pull-down assay of ynone-LLZ to identify the biomolecular target, and developed the new synthetic route of Ynone-LLZ and the chemical probe because the previous synthetic route could not applied to the synthesis of the probe.
|
| Free Research Field |
医薬化学
|
| Academic Significance and Societal Importance of the Research Achievements |
申請者は、多発性骨髄腫に対して顕著な治癒効果を示す新規低分子化合物を見出しており、これが副作用リスクの低い骨髄腫治療薬になり得る可能性を示してきた。しかし、このような有望な生物活性がどのような生体内作用標的に作用することで引き起こされているかは未知であった。今回の研究では、その生体内作用標的に迫るために必須な化学プローブ合成に主眼を置いている。これが達成され、生体内作用標的が明らかとなれば、新たな多発性骨髄腫治療薬開発の加速が期待される。
|
